Management of Mixed-Phenotype Acute Leukemia in the East of France

Study Overview
=================
Brief Summary
-----------------
Clinical presentation and management of Mixed-Phenotype Acute leukemia (MPAL) is heterogeneous. This descriptive observationnal study aims to review MPAL cases in the East of France based on a 10-year multicentre retrospective collection.

Official Title
-----------------
Management of Mixed-Phenotype Acute Leukemia in the East of France

Conditions
-----------------
Mixed Phenotype Acute Leukemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients over 18 years of age Diagnosis of biphenotypic acute leukemia or mixed-phenotype acute leukemia between 2008 and 2018

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Age of the patients when diagnosed with MPAL | Age in years | At inclusion (Day 0) | 
| Sex of the patients when diagnosed with MPAL | Male or female | At inclusion (Day 0) | 
| City of the hematology unit in charge of each patient for the treatment of MPAL | Nancy, Metz-Thionville, Reims, Strasbourg, Mulhouse, Dijon or Besançon | At inclusion (Day 0) | 
| MPAL rate in the each hematology unit | Rate of MPAL out of the total number of patients diagnosed with acute leukemia in each hematology unit | 10 years (01/01/2008-01/01/2018) | 
| Date of MPAL diagnosis for each patient |  | At inclusion (Day 0) | 
| Type of MPAL for each patient | De novo MPAL or secondary to myelodysplasia MPAL | At inclusion (Day 0) | 
| Percentage of blood blasts for each patient at diagnosis of MPAL | On the first blood sample analyzed | At inclusion (D0) | 
| Percentage of medullar blasts for each patient at diagnosis of MPAL | On the first bone marrow sample analyzed | At inclusion (Day 0) | 
| Cytologic characteristics: type of myeloid markers at diagnosis for each patient | Presence or not of myeloid markers generally sought in the diagnosis of acute leukaemias | At inclusion (Day 0) | 
| Cytologic characteristics: type of B lymphoid markers at diagnosis for each patient | Presence or not of B lymphoid markers generally sought in the diagnosis of acute leukaemias | At inclusion (Day 0) | 
| Cytologic characteristics: type of T lymphoid markers | Presence or not of T lymphoid markers generally sought in the diagnosis of acute leukemias | At inclusion (D0) | 
| Medullar MPO positivity percentage at diagnosis for each patient | If performed on the bone marrow sample used to confirm the diagnosis | At inclusion (Day 0) | 
| Genetic characteristics on the caryotype at diagnosis for each patient | Presence or not of caryotypic abnormalities generally sought in the diagnosis of acute leukemias | At inclusion (Day 0) | 
| Genetic characteristics on molecular biology analysis at diagnosis for each patient | Presence or not of molecular biology abnormalities generally sought in the diagnosis of acute leukemias | At inclusion (D0) | 
| Classification of biphenotypic acute leukemia (BAL) according to the EGIL 1998 criterias at diagnosis | BAL or not | At inclusion (Day 0) | 
| Classification of MPAL according to the WHO 2008 criterias at diagnosis | MPAL or not | At inclusion (Day 0) | 
| Type of treatments and dates of the first day of every treatment line for each patient | Myeloid or lymphoid chemotherapy regimen | 10 years (01/01/2008-01/01/2018) | 
| Medullar response for every treatments line for each patient | Complete cytological and molecular response or treatment failure | 10 years (01/01/2008-01/01/2018) | 
| Treatment including allogenic hematopoietic stem cells transplant (HSCT) (yes or no) with type of conditionning regimen for each patient | High-dose, reduced-intensity or nonmyeloablative conditioning regimens with or without total body irradiation | 10 years (01/01/2008-01/01/2018) | 
| HSCT complicated with acute and/or chronic graft-versus-host disease with severity grade and treatments for each patient | Diagnosis of GVHD according to Filipovich criterias (BMT 2005); Severity grade according to Seattle criterias; Type of treatments: steroids, other immunosuppressive agents, extracorporeal photopheresis | 10 years (01/01/2008-01/01/2018) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Date of every relapse for each patient |  | 10 years (01/01/2008-01/01/2018) | 
| Date of death if occured |  | 10 years (01/01/2008-01/01/2018) | 
| Cause of death | Secondary to leukemia, treatment or other cause | 10 years (01/01/2008-01/01/2018) |